Adam B Weiner1, Farzana A Faisal2, Elai Davicioni3, R Jeffrey Karnes4, Donald J Vander Griend5, Tamara L Lotan6, Edward M Schaeffer7. 1. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 2. Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Decipher Biosciences, Vancouver, BC, Canada. 4. Department of Urology, Mayo Clinic Rochester, Rochester, MN, USA. 5. Department of Pathology, The University of Illinois at Chicago, Chicago, IL, USA. 6. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 7. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address: e-schaeffer@northwestern.edu.
Abstract
BACKGROUND: Homeobox B13 (HOXB13) expression regulates normal prostate development and mutations are associated with prostate cancer (PCa) formation. OBJECTIVE: To assess the role of HOXB13 mRNA expression in PCa progression following radical prostatectomy. DESIGN, SETTING, AND PARTICIPANTS: Genome-wide expression profiles were queried from two retrospective prostatectomy cohorts with follow-up data (Mayo Clinic, n=780; Johns Hopkins Medical Institute [JHMI], n=355), and a prospective genomic registry (n=5239). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox regressions were used to analyze metastasis-free survival (MFS). RESULTS AND LIMITATIONS: HOXB13 expression in primary PCa increased with increasing tumor grade and with high metastatic potential based on a genomic signature. The highest quartile of HOXB13 expression was associated with worse MFS compared with the lowest quartile (Mayo Clinic: adjusted hazard ratio [AHR] 1.46, 95% confidence interval [CI] 1.03-2.06, and JHMI: AHR 1.80, 95% CI 1.02-3.19). The combinations of high HOXB13 expression and low expression of its binding partner, MEIS1 (AHR 2.03, 95% CI 1.54-2.66) or MEIS2 (AHR 1.73, 95% CI 1.33-2.26), portended worse MFS. Additionally, high HOXB13 expression in combination with low MEIS1/2 expression correlated with high expression of androgen receptor-mediated genes. The retrospective nature of this study subjects the findings to a bias due to unmeasured variables. CONCLUSIONS: Primary PCa tumors with increased HOXB13 expression have an increased propensity for metastases following prostatectomy, particularly in the setting of low MEIS1/2 expression. High androgen receptor output may account for worse outcomes for these tumors and suggests heightened sensitivity to androgen suppression. PATIENT SUMMARY: Using genomic data from a large number of prostate cancer (PCa) tumors, we found that increased expression of homeobox B13 (HOXB13), a gene related to normal prostate development, was associated with worse outcomes following surgery for PCa. A biomarker signature suggests that these tumors would be more susceptible to androgen suppression, a common treatment for PCa. Take Home Messagece:: In multiple large cohorts, prostate cancer tumors with high homeobox B13 (HOXB13) expression and low expression of its binding partner MEIS1/2 were enriched with high androgen receptor output and had an increased propensity for metastases following surgery.
BACKGROUND: Homeobox B13 (HOXB13) expression regulates normal prostate development and mutations are associated with prostate cancer (PCa) formation. OBJECTIVE: To assess the role of HOXB13 mRNA expression in PCa progression following radical prostatectomy. DESIGN, SETTING, AND PARTICIPANTS: Genome-wide expression profiles were queried from two retrospective prostatectomy cohorts with follow-up data (Mayo Clinic, n=780; Johns Hopkins Medical Institute [JHMI], n=355), and a prospective genomic registry (n=5239). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox regressions were used to analyze metastasis-free survival (MFS). RESULTS AND LIMITATIONS: HOXB13 expression in primary PCa increased with increasing tumor grade and with high metastatic potential based on a genomic signature. The highest quartile of HOXB13 expression was associated with worse MFS compared with the lowest quartile (Mayo Clinic: adjusted hazard ratio [AHR] 1.46, 95% confidence interval [CI] 1.03-2.06, and JHMI: AHR 1.80, 95% CI 1.02-3.19). The combinations of high HOXB13 expression and low expression of its binding partner, MEIS1 (AHR 2.03, 95% CI 1.54-2.66) or MEIS2 (AHR 1.73, 95% CI 1.33-2.26), portended worse MFS. Additionally, high HOXB13 expression in combination with low MEIS1/2 expression correlated with high expression of androgen receptor-mediated genes. The retrospective nature of this study subjects the findings to a bias due to unmeasured variables. CONCLUSIONS: Primary PCa tumors with increased HOXB13 expression have an increased propensity for metastases following prostatectomy, particularly in the setting of low MEIS1/2 expression. High androgen receptor output may account for worse outcomes for these tumors and suggests heightened sensitivity to androgen suppression. PATIENT SUMMARY: Using genomic data from a large number of prostate cancer (PCa) tumors, we found that increased expression of homeobox B13 (HOXB13), a gene related to normal prostate development, was associated with worse outcomes following surgery for PCa. A biomarker signature suggests that these tumors would be more susceptible to androgen suppression, a common treatment for PCa. Take Home Messagece:: In multiple large cohorts, prostate cancer tumors with high homeobox B13 (HOXB13) expression and low expression of its binding partner MEIS1/2 were enriched with high androgen receptor output and had an increased propensity for metastases following surgery.
Authors: Dorhyun Johng; Gonzalo Torga; Charles M Ewing; Kideok Jin; John D Norris; Donald P McDonnell; William B Isaacs Journal: Prostate Date: 2018-12-17 Impact factor: 4.104
Authors: Matthew R Cooperberg; Peter R Carroll; Marc A Dall'Era; Benjamin J Davies; John W Davis; Scott E Eggener; Felix Y Feng; Daniel W Lin; Todd M Morgan; Alicia K Morgans; Daniel E Spratt; Samir S Taneja; David F Penson Journal: Eur Urol Date: 2019-05-23 Impact factor: 20.096
Authors: Renu Jeyapala; Andrea J Savio; Ekaterina Olkhov-Mitsel; Shivani Kamdar; Fang Zhao; Carmelle Cuizon; Richard S C Liu; Alex Zlotta; Neil Fleshner; Theodorus van der Kwast; Bharati Bapat Journal: Eur Urol Oncol Date: 2018-09-01
Authors: Daniel E Spratt; Mohammed Alshalalfa; Nick Fishbane; Adam B Weiner; Rohit Mehra; Brandon A Mahal; Jonathan Lehrer; Yang Liu; Shuang G Zhao; Corey Speers; Todd M Morgan; Adam P Dicker; Stephen J Freedland; R Jeffery Karnes; Sheila Weinmann; Elai Davicioni; Ashley E Ross; Robert B Den; Paul L Nguyen; Felix Y Feng; Tamara L Lotan; Arul M Chinnaiyan; Edward M Schaeffer Journal: Clin Cancer Res Date: 2019-09-12 Impact factor: 12.531
Authors: Maurice P H M Jansen; Anieta M Sieuwerts; Maxime P Look; Kirsten Ritstier; Marion E Meijer-van Gelder; Iris L van Staveren; Jan G M Klijn; John A Foekens; Els M J J Berns Journal: J Clin Oncol Date: 2007-02-20 Impact factor: 44.544
Authors: Daniel E Spratt; Kasra Yousefi; Samineh Deheshi; Ashley E Ross; Robert B Den; Edward M Schaeffer; Bruce J Trock; Jingbin Zhang; Andrew G Glass; Adam P Dicker; Firas Abdollah; Shuang G Zhao; Lucia L C Lam; Marguerite du Plessis; Voleak Choeurng; Zaid Haddad; Christine Buerki; Elai Davicioni; Sheila Weinmann; Stephen J Freedland; Eric A Klein; R Jeffrey Karnes; Felix Y Feng Journal: J Clin Oncol Date: 2017-03-30 Impact factor: 44.544
Authors: Mark M Pomerantz; Fugen Li; David Y Takeda; Romina Lenci; Apurva Chonkar; Matthew Chabot; Paloma Cejas; Francisca Vazquez; Jennifer Cook; Ramesh A Shivdasani; Michaela Bowden; Rosina Lis; William C Hahn; Philip W Kantoff; Myles Brown; Massimo Loda; Henry W Long; Matthew L Freedman Journal: Nat Genet Date: 2015-10-12 Impact factor: 38.330
Authors: Duy T Nguyen; Wei Yang; Kiran Mahajan; Arun Renganathan; Cody Weimholt; Duminduni H Angappulige; Thanh Nguyen; Robert W Sprung; Gerald L Andriole; Eric H Kim; Nupam P Mahajan Journal: Clin Cancer Res Date: 2022-09-15 Impact factor: 13.801
Authors: Philip Sutera; Matthew P Deek; Kim Van der Eecken; Alexander W Wyatt; Amar U Kishan; Jason K Molitoris; Matthew J Ferris; M Minhaj Siddiqui; Zaker Rana; Mark V Mishra; Young Kwok; Elai Davicioni; Daniel E Spratt; Piet Ost; Felix Y Feng; Phuoc T Tran Journal: Prostate Date: 2022-08 Impact factor: 4.012
Authors: P Porras-Quesada; J M González-Cabezuelo; V Sánchez-Conde; I Puche-Sanz; V Arenas-Rodríguez; C García-López; J F Flores-Martín; J M Molina-Hernández; M J Álvarez-Cubero; L J Martínez-González; F Vázquez-Alonso Journal: Front Genet Date: 2022-01-04 Impact factor: 4.599